The findings demonstrated that the degradation products notably enhanced glucose metabolism disorders by targeting and modulating the interaction between the Nrf2/NQO1/HO-1 antioxidant pathway and the PI3K/Akt/GSK3β insulin signaling pathway. The gene discussed is HMOX1; the disease is glucose measurement.